Condensed Consolidated Balance Sheets - USD ($) $ in Millions	Mar. 31, 2020	Jun. 30, 2019
Current assets:
Cash and cash equivalents	$ 121.0	$ 93.2
Marketable investment securities	60.5	43.7
Prepaid expenses	12.5	16.6
Inventory	30.8	31.4
Trade accounts receivable	102.5	133.9
Prepaid taxes	25.4	25.1
Other receivables	2.5	4.7
Total current assets	355.2	348.6
Property, plant and equipment, net	37.1	57.3
Operating lease right-of-use assets	64.5
Long-term marketable investment securities	42.8	54.9
Intangibles, net	620.0	684.7
Goodwill	327.1	417.2
Total assets	1,446.7	1,562.7
Current liabilities:
Accounts payable	30.3	33.3
Accrued liabilities	63.1	78.9
Current maturities of operating lease liabilities	12.9
Short-term contingent consideration	3.1	3.4
Deferred revenue	3.8	2.2
Total current liabilities	113.2	117.8
Unrecognized tax benefits	22.3	21.7
Noncurrent operating lease liabilities	55.9
Other long-term liabilities		7.8
Contingent consideration	3.6	10.4
Long-term debt	225.2	233.5
Long-term deferred taxes	59.3	82.6
Total liabilities	479.5	473.8
Commitments and contingencies
Stockholders’ equity:
Common stock, 74.5 and 73.5 shares outstanding at March 31, 2020 and June 30, 2019 respectively	0.7	0.7
Additional paid-in capital	1,092.8	1,068.0
Accumulated other comprehensive loss	(7.8)	(5.4)
Retained earnings (deficit)	(118.5)	25.6
Total Myriad Genetics, Inc. stockholders’ equity	967.2	1,088.9
Total stockholders' equity	967.2	1,088.9
Total liabilities and stockholders’ equity	$ 1,446.7	$ 1,562.7